Neurochem announces departure of two members of manag...(itions general conditions in thepharmace...),Health
Navigation Links
Neurochem announces departure of two members of management team
Date:2/21/2008
itions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.
Lise Hebert, PhD, Vice President, Corporate Communications, (450) 680-4572, lhebert@neurochem.com
'/>"/>
| SOURCE NEUROCHEM INC. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
2. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
3. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
4. Neurochem to present at JPMorgan Healthcare Conference
5. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
6. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
7. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
8. Neurochem reports results for third quarter of fiscal 2007
9. Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program
10. LCA-Vision Announces Quarterly Dividend Payment
11. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
Post Your Comments:
(Date:11/26/2009)...ons announces a highly effective and unconventiona...to make an economic recovery. , ...he type of challenge that could send ailing holida...vid Benton, business growth expert and author of t...The Rfactor Intensive . “Fear is one of th...
(Date:11/25/2009)...-SentinelleMedicalInc.,aleadingmanufacturerofMagne...ScientificInc.,aleadingproviderofsoftwareenablingt...east4DAdvancedVisualizationsoftware. ,, Thisinn...ientbasedmedicalimagingofferinginthemarket.Calgary...rintaccess-requiringnosoftwaredownload,andrunsonan...
(Date:11/25/2009)...BayAreaAirQualityManagementDistrictisissuingthesea... forThursday,November26,2009whichbansburningwood,...sandoutdoors. ,, "Cold,stillweatherwillcontribu...,executiveofficeroftheAirDistrict."We,reaskingBayA...ellowcommunitymembersthisThanksgiving,andnottoburn...
(Date:11/25/2009)... simple question has been the focus of intense res...ulates High Blood Pressure in Mice & Men, Does st...n has been the focus of intense research for many ...tablished a link between a novel gene, phosducin, ...as well as humans. The studies were directed by sc...
(Date:11/25/2009)...toms, study finds , , WEDNESDAY, Nov. 2...e among the potential problems faced by long-term ...th cisplatin-based chemotherapy, a new study has f...treated for unilateral testicular cancer between 1...onducted from 1998 to 2002. , The researchers f...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2[0] Pharmacist Injects Cure for Ailing Businesses [1] Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology[0] Winter Spare the Air Alert in Effect for Thursday, November 26, 2009[0] New stress-related gene modulates high blood pressure in mice and men[0] Long-Term Problems Linked to Testicular Cancer Chemo
...(Nasdaq: PARS ) announced today that it has comp...extofisopam trial for Irritable Bowel Syndrome IBS...ld achieve the objectives of the trial. As the Ph...(1) determine the best dose to move into Phase 3, ...
...row? , , WASHINGTON, March 4 The Association of ... following statement by Kathryn Serkes, Director o...nt,s Healthcare Summit on March 5, 2009: , , "We... lost in the mail. , , "It,s interesting that r...
...as in general, study suggests , , WEDNESDA...at increase cocaine addicts, risk of paranoia have...tudy of almost 4,000 people of African and Europea...aine dependence and cocaine-induced paranoia. , Th...
...e, the first South Florida publication dedicated t..., nutrition, health and sports for men and women, ... the 2009 FAME Awards (FOLIO: Awards for Magazine ...n magazine-powered events, SOBeFiT beat out fina...
...t in a 6-3 decision upheld a Vermont jury,s decisi... Court case Wyeth v. Levine could hold the drug ma...ed -- which included the loss of her arm -- after ...rsight of drug labeling doesn,t prevent the filing...
... Inc. (OTC Bulletin Board: BKYI), a leader in wire...tification solutions, today announced that on or b...tates District Court for the Southern District of ...their complaint, those investors have alleged that...
Other Medicine News:Health News:Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved 2Health News:Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved 3Health News:AAPS Doctors: White House Healthcare 'Prom' Invitations 'Lost in the Mail' 2Health News:Gene Variant Tied to Cocaine-Induced Paranoia 2Health News:SOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME Awards 2Health News:SOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME Awards 3Health News:SOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME Awards 4Health News:BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 2Health News:BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 3Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be AchievedAAPS Doctors: White House Healthcare 'Prom' Invitations 'Lost in the Mail'Gene Variant Tied to Cocaine-Induced ParanoiaSOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME AwardsAAJ Statement on Supreme Court Decision in Favor of Diana LevineBIO-key to Respond in Court to a Lawsuit Filed by Two Investors
(Date:11/25/2009)...landsandJOHANNESBURG,November25/PRNewswire/--,iThe...yannouncedtoday,thattheyhavesignedacollaborativeag..., Pyxis,sworldclasscomputationalchemistryandlead...cedivisiontoprovidemedicinaland,syntheticchemistry...onalclientnetwork.iThembaPharmaceuticalsandPyxisDi...
(Date:11/25/2009)...lif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,annou...,sPROTECT-1(theProspectiveRandomizedOralTherapyEva...282-B)inpatientswithmoderate-to-severeCrohn,sdisea...andtolerabilityprofile.Thestudydemonstratedevidenc...asdefinedasa70-pointdecreaseintheCrohn,sDiseaseAct...
(Date:11/24/2009)...24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgianman...cident,wasactuallyfullyconsciousandawakeduringthat...heDynaVoxEyeMaxwasfeaturedinthesegmenttoillustrate...nunlockcommunication. ,, WHEN:GoodMorningAmeric...navoxtech.com ,, WHO:RomHoubenswasanenginee...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Total Nonstop Action 28TNA 29 Wrestling Gets Energized with the Extreme Energy Shot 21 47998 1Total Nonstop Action 28TNA 29 Wrestling Gets Energized with the Extreme Energy Shot 21 47998 2NxStage to Present at the William Blair Growth Stock Conference 47994 1NxStage to Present at the William Blair Growth Stock Conference 47994 2Herb May Offer Hope for Autoimmune Diseases 47990 1Herb May Offer Hope for Autoimmune Diseases 47990 2Herb May Offer Hope for Autoimmune Diseases 47990 3[0] iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering[0] ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference[0] DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years
...ed (ASX: POH, AIM: PSG, OTCQX: PPGNY) and Nestle N...ointly commence a phase 2 human clinical,trial in ...cs, Phospha E(R),in the management of metabolic sy...uct the double-blind phase 2,clinical trial, which...racterized by a group of risk factors that,increas...
...ring Therapies Experienced, 46% Further Reductions...2 for 13 Weeks, - St...osium in New York ...y, October 8, at 8:00 a.m. E.T. ...alif., Oct. 4 Isis,Pharmaceuticals, Inc. (Nasdaq:...
Other Medicine Technology:Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 2Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 3Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 6| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |